Last edition
News about Global Pharma
Capricor Therapeutics Updates on Deramiocel BLA for Duchenne Muscular Dystrophy
Capricor Therapeutics has announced progress on its Biologics License Application for Deramiocel, its lead cell therapy for DMD-associated cardiomyopathy, with the FDA maintaining Priority Review and no Advisory Committee meeting planned ahead of the August 31, 2025 PDUFA date.
Global Pharma | 26/06/2025 | By Manvi | 189
Lupin Secures US FDA Approval for Prucalopride Tablets
Lupin has received US FDA approval for its generic Prucalopride Tablets, 1 mg and 2 mg, for the treatment of chronic idiopathic constipation (CIC) in adults. This product will be manufactured at Lupin's Goa facility in India.
Global Pharma | 25/06/2025 | By Manvi | 188
Nitinotes Receives FDA Approval to Initiate Pivotal Trial for EndoZip Suturing System
Nitinotes, developer of the EndoZip™ System announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal clinical trial under an Investigational Device Exemption (IDE).
Global Pharma | 25/06/2025 | By Manvi | 170
Illumina to Acquire SomaLogic for USD 350 Million to Accelerate its Proteomics Business
Illumina has announced a definitive agreement to acquire proteomics firm SomaLogic and other assets from Standard BioTools for up to USD 425 million, strengthening its multiomics strategy and expanding its footprint in the fast-growing proteomics market.
Global Pharma | 24/06/2025 | By Manvi | 147
Cerapedics Receives FDA Approval for PearlMatrix Bone Graft
Cerapedics Inc. announced the U.S. Food and Drug Administration (FDA) premarket approval (PMA) of PearlMatrix™ P-15 Peptide Enhanced Bone Graft as a Class III drug-device combination product for use in single-level transforminal lumbar interbody fusion (TLIF) surgery in adult patients with degenerative disc disease (DDD).
Global Pharma | 24/06/2025 | By Manvi | 884
Glenmark Launches TEVIMBRA in India for Lung and Esophageal Cancer Treatment
Glenmark Pharmaceuticals has launched TEVIMBRA (tislelizumab) in India, marking its entry into immuno-oncology with a globally approved PD-1 inhibitor for advanced lung and esophageal cancers.
Global Pharma | 24/06/2025 | By Manvi | 205
PharmaJet, Immuno Cure Partner for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
PharmaJet has partnered with Immuno Cure to provide its needle-free Tropis ID system for delivering ICVAX, a novel therapeutic HIV-1 DNA vaccine, in a human clinical trial—aiming to enhance vaccine performance and patient experience while advancing toward a functional HIV cure.
Global Pharma | 23/06/2025 | By Manvi | 125
IONETIX and AlfaRim Announce Strategic Collaboration on Cyclotron-Produced Actinium-225
IONETIX and AlfaRim announced a strategic collaboration to commercialize cyclotron-produced actinium-225, a key isotope enabling next-generation targeted alpha therapies (TATs).
Global Pharma | 23/06/2025 | By Manvi | 255
Under the agreement, TerraPower Isotopes would supply Ratio with quantities of non-cGMP Ac-225 for use to incorporate into or use in the development of Ratio's radiopharmaceuticals.
Global Pharma | 21/06/2025 | By Manvi | 166
Catalyst MedTech Named Exclusive US Distributor of CareMiBrain
Catalyst MedTech has announced it will serve as the exclusive US distributor of CareMiBrain™, an ultra-high resolution dedicated brain PET system developed by MindView / OncoVision.
Global Pharma | 21/06/2025 | By Manvi | 101
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy